Results 101 to 110 of about 39,319 (333)

Inhibition of Btk by Btk-specific concentrations of ibrutinib and acalabrutinib delays but does not block platelet aggregation mediated by glycoprotein VI

Haematologica, 2018
Ibrutinib and acalabrutinib are irreversible inhibitors of Bruton tyrosine kinase used in the treatment of B-cell malignancies. They bind irreversibly to cysteine 481 of Bruton tyrosine kinase, blocking autophosphorylation on tyrosine 223 and ...
Phillip L.R. Nicolson, Craig E. Hughes, Stephanie Watson, Sophie H. Nock, Alexander T. Hardy, Callum N. Watson, Samantha J. Montague, Hayley Clifford, Aarnoud P. Huissoon, Jean-Daniel Malcor, Mark R. Thomas, Alice Y. Pollitt, Michael G. Tomlinson, Guy Pratt, Steve P. Watson   +14 more
doaj   +1 more source

Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse

Biomarker Research, 2020
Background Ibrutinib, an irreversible Bruton Tyrosine Kinase (BTK) inhibitor, has revolutionized Chronic Lymphocytic Leukemia (CLL) treatment, but resistances to ibrutinib have emerged, whether related or not to BTK mutations.
Sarah Cadot, Carine Valle, Marie Tosolini, Frederic Pont, Laetitia Largeaud, Camille Laurent, Jean Jacques Fournie, Loic Ysebaert, Anne Quillet-Mary   +8 more
doaj   +1 more source

HBV messing with the B-cell genome leads to DLBCL [PDF]

, 2018
non ...
Casato, Milvia, Visentini, Marcella
core   +1 more source

Mycosis Fungoides, Sézary Syndrome, and Cutaneous B‐Cell Lymphomas: 2025 Update on Diagnosis, Risk‐Stratification, and Management

American Journal of Hematology, EarlyView.
ABSTRACT Disease Overview Primary cutaneous lymphomas are a rare and heterogeneous group of extranodal lymphomas that require the integration of clinical and histopathologic data for classification and treatment. Diagnosis Diagnosis and disease classification is based on histopathologic review and immunohistochemical staining of an appropriate skin ...
Alexandra C. Hristov, Trilokraj Tejasvi, Ryan A. Wilcox   +2 more
wiley   +1 more source

Concurrent ibrutinib plus venetoclax in relapsed/refractory mantle cell lymphoma: the safety run-in of the phase 3 SYMPATICO study

Journal of Hematology & Oncology, 2021
Ibrutinib plus venetoclax, given with an ibrutinib lead-in, has shown encouraging clinical activity in early phase studies in mantle cell lymphoma (MCL).
Michael Wang, Radhakrishnan Ramchandren, Robert Chen, Lionel Karlin, Geoffrey Chong, Wojciech Jurczak, Ka Lung Wu, Mark Bishton, Graham P. Collins, Paul Eliadis, Frédéric Peyrade, Yihua Lee, Karl Eckert, Jutta K. Neuenburg, Constantine S. Tam   +14 more
doaj   +1 more source

Cirmtuzumab inhibits Wnt5a-induced Rac1 activation in chronic lymphocytic leukemia treated with ibrutinib. [PDF]

, 2017
Signaling via the B cell receptor (BCR) plays an important role in the pathogenesis and progression of chronic lymphocytic leukemia (CLL). This is underscored by the clinical effectiveness of ibrutinib, an inhibitor of Bruton's tyrosine kinase (BTK) that
Chen, L, Chen, Y, Choi, MY, Cui, B, Kipps, TJ, Rassenti, LZ, Widhopf Ii, GF, Wu, Christina, Yu, J, Zhang, L   +9 more
core  

Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia. [PDF]

, 2017
BackgroundThe CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL.
Amaya-Chanaga, Carlos I, Amine, Ale-Ali, Castro, Januario E, Choi, Michael Y, Fantin, Valeria R, Gu, Yin, Hallin, Max, Huser, Nanni, Kashyap, Manoj K, Kipps, Thomas J, Kumar, Deepak, Lindquist, Kevin, Liu, Shu-Hui, Pernasetti, Flavia, Rassenti, Laura Z, Simmons, Brett, Smeal, Tod, Yafawi, Rolla, Zhang, Cathy   +18 more
core   +4 more sources

A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL

Blood Advances, 2022
Key Points • Patients with DLBCL Richter transformation of CLL have a poor prognosis, especially if they have had prior BTKi exposure.• Nivolumab and ibrutinib combination therapy is a safe and potential treatment option in patients with DLBCL Richter ...
N. Jain, J. Senapati, B. Thakral, A. Ferrajoli, P. Thompson, J. Burger, Sreyashi Basu, T. Kadia, N. Daver, G. Borthakur, M. Konopleva, N. Pemmaraju, E. Parry, Catherine J. Wu, J. Khoury, C. Bueso-Ramos, Naveen Garg, Xuemei Wang, W. Lopez, A. Ayala, S. O'brien, H. Kantarjian, M. Keating, J. Allison, Padmanee Sharma, W. Wierda   +25 more
semanticscholar   +1 more source

New Horizons for Multiple Sclerosis Therapy: 2025 and Beyond

Annals of Neurology, EarlyView.
The advances achieved against multiple sclerosis (MS) represent one of the great success stories of modern molecular medicine. The development of therapies with increasing selectivity and safety, guided by gains in understanding the fundamental immunology, neurobiology, genetics, and triggers of this disease, have broadened the traditional focus on ...
Joseph J. Sabatino Jr., Bruce A. C. Cree, Stephen L. Hauser   +2 more
wiley   +1 more source

Preclinical evaluation of the Hsp90 inhibitor SNX-5422 in ibrutinib resistant CLL

Journal of Hematology & Oncology, 2021
B-cell receptor (BCR) antagonists such as the BTK inhibitor ibrutinib have proven to effectively target chronic lymphocytic leukemia (CLL) tumor cells, leading to impressive response rates in these patients. However patients do still relapse on ibrutinib,
Timothy L. Chen, Bonnie Harrington, Jean Truxall, Ronni Wasmuth, Alexander Prouty, Shelby Sloan, Amy M. Lehman, Deepa Sampath, Eric Orlemans, Robert A. Baiocchi, Lapo Alinari, John C. Byrd, Jennifer A. Woyach, Erin Hertlein   +13 more
doaj   +1 more source